A detailed history of China Universal Asset Management Co., Ltd. transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 3,514 shares of LGND stock, worth $429,902. This represents 0.04% of its overall portfolio holdings.

Number of Shares
3,514
Previous 2,112 66.38%
Holding current value
$429,902
Previous $177,000 98.31%
% of portfolio
0.04%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$82.7 - $110.11 $115,945 - $154,374
1,402 Added 66.38%
3,514 $351,000
Q2 2024

Jul 19, 2024

SELL
$68.53 - $87.91 $90,802 - $116,480
-1,325 Reduced 38.55%
2,112 $177,000
Q1 2024

Apr 29, 2024

BUY
$68.64 - $89.2 $97,812 - $127,110
1,425 Added 70.83%
3,437 $251,000
Q4 2023

May 21, 2024

SELL
$49.57 - $72.63 $70,637 - $103,497
-1,425 Reduced 41.46%
2,012 $143,000
Q4 2023

Jan 23, 2024

BUY
$49.57 - $72.63 $77,874 - $114,101
1,571 Added 356.24%
2,012 $144,000
Q3 2023

May 21, 2024

BUY
$58.86 - $72.67 $12,654 - $15,624
215 Added 95.13%
441 $26,000
Q3 2023

Oct 30, 2023

BUY
$58.86 - $72.67 $12,654 - $15,624
215 Added 95.13%
441 $26,000
Q2 2023

May 21, 2024

SELL
$69.53 - $79.33 $347 - $396
-5 Reduced 2.16%
226 $16,000
Q2 2023

Jul 27, 2023

SELL
$69.53 - $79.33 $347 - $396
-5 Reduced 2.16%
226 $16,000
Q1 2023

May 21, 2024

BUY
$65.67 - $77.08 $3,940 - $4,624
60 Added 35.09%
231 $16,000
Q1 2023

Apr 27, 2023

BUY
$65.67 - $77.08 $3,940 - $4,624
60 Added 35.09%
231 $17,000
Q4 2022

May 21, 2024

SELL
$61.72 - $96.74 $201,577 - $315,952
-3,266 Reduced 95.02%
171 $11,000
Q4 2022

Jan 31, 2023

BUY
$61.72 - $96.74 $740 - $1,160
12 Added 7.55%
171 $11,000
Q3 2022

Oct 21, 2022

BUY
$0.01 - $107.56 $1 - $17,102
159 New
159 $14,000

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $2.07B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.